This week's Pod looks at the 2nd CD20-CD3 bispecific T-Cell engager approved this year (or at all), glofitamab, and the TALAPRO-2 study of combining talazoparib to enzalutaimide.

TALAPRO-2: https://doi.org/10.1016/S0140-6736(23)01055-3